Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia

Frontiers in Pediatrics

Haneen Shalabi¹ 

关键词: chimeric antigen receptor;    immunotherapy;    adoptive;    relapsed leukemia;    chimeric antigen receptor safety;    pediatric acute leukemia;   

DOI  :  10.3389/fped.2015.00080

学科分类：儿科学

来源: Frontiers

【 摘 要 】

Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult to treat with conventional therapy due to dose-limiting toxicities. With the recent success of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this mode of therapy has become a very attractive option for these patients with high-risk disease. In this review, we will discuss current treatment paradigms of pediatric acute leukemia and potential therapeutic targets for additional high-risk populations, including T cell ALL, AML, and infant ALL.

【 授权许可】

CC BY